HC Wainwright reissued their buy rating on shares of VYNE Therapeutics (NASDAQ:VYNE - Free Report) in a research note published on Tuesday,Benzinga reports. HC Wainwright currently has a $5.75 price objective on the stock.
Separately, BTIG Research initiated coverage on VYNE Therapeutics in a research report on Monday, November 18th. They issued a "buy" rating and a $8.00 price target on the stock.
View Our Latest Stock Report on VYNE
VYNE Therapeutics Trading Down 8.9 %
VYNE traded down $0.27 during trading on Tuesday, reaching $2.75. 101,652 shares of the company's stock were exchanged, compared to its average volume of 190,619. The firm has a fifty day moving average price of $2.98 and a two-hundred day moving average price of $2.35. The stock has a market capitalization of $40.57 million, a PE ratio of -3.20 and a beta of 1.30. VYNE Therapeutics has a one year low of $1.57 and a one year high of $4.30.
Institutional Trading of VYNE Therapeutics
An institutional investor recently bought a new position in VYNE Therapeutics stock. Lynx1 Capital Management LP bought a new stake in shares of VYNE Therapeutics Inc. (NASDAQ:VYNE - Free Report) during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund bought 16,194 shares of the company's stock, valued at approximately $32,000. VYNE Therapeutics accounts for approximately 0.0% of Lynx1 Capital Management LP's portfolio, making the stock its 17th largest holding. Lynx1 Capital Management LP owned 0.11% of VYNE Therapeutics at the end of the most recent reporting period. 83.78% of the stock is owned by hedge funds and other institutional investors.
About VYNE Therapeutics
(
Get Free Report)
VYNE Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing proprietary and therapeutics for the treatment of immuno-inflammatory conditions. The company's lead product is VYN201, a locally administered pan- bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways with low systemic exposure.
Featured Articles
Before you consider VYNE Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and VYNE Therapeutics wasn't on the list.
While VYNE Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
